Journal
ONCOIMMUNOLOGY
Volume 2, Issue 11, Pages -Publisher
LANDES BIOSCIENCE
DOI: 10.4161/onci.26512
Keywords
CD8(+) T cells; CD40L; dendritic cells; IL-12; melanoma; vaccines
Categories
Ask authors/readers for more resources
Dendritic cell (DC)-based anticancer vaccines have yielded disappointing results in a multitude of clinical trials. New data suggest that the clinical efficacy of DC-based vaccines may be dependent on the paracrine production of interleukin-12 in the course of antigen presentation and the consequent development of therapeutic Type 1 CD8(+) T-cell immunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
